Listen on the go
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Download Slides
    Download Practice Aid
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Mitchell L Shiffman

    Bon Secours Liver Institute, Richmond, VA, USA

    Dr Mitchell L Shiffman is the director of the Liver Institute of Virginia at Bon Secours Mercy Health, Richmond, VA, USA, which he founded in 2010. read more

    He graduated from the State University of New York Upstate Medical Center in Syracuse before completing residency training in internal medicine and a fellowship training in gastroenterology and hepatology at the Medical College of Virginia in Richmond. From 1990 to 2009, Dr Shiffman was chief of the Hepatology Section and medical director of the Liver Transplant Program at the Virginia Commonwealth University Medical Center in Richmond.

    Dr Shiffman has published over 350 articles in peer- reviewed medical journals, invited reviews and/or book chapters; has edited three textbooks on liver disease; and has been the guest editor for two issues of Clinics in Liver Disease.

    He is a fellow of the American Association for the Study of Liver Diseases (AASLD), was a member of the board of trustees of the American College of Gastroenterology (ACG) from 2004 to 2010, and has been recognized as a Master Physician of the ACG.

    Dr Mitchell L Shiffman discloses: Advisory board or panel fees from CymaBay, Exelixis, Gilead, HepQuant, Intercept, Ipsen and Mirum. Grants/research support from 89 Bio, Akero, Altimmune, Camurus, Durect, Galectin, Genentech, Gilead, HepQuant, Hamni, High Tide, Intercept, Inventiva, Ipsen, Madrigal, Mirum, Novo Nordisk, Oncoustics, Pliant, Salix, Viking Therapeutics and Zydus. Speaker Bureau fees from Genentech, Gilead, Intercept, Ipsen, Madrigal and Mallinckrodt.
    touchIMMUNOLOGY touchIMMUNOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Liver Disorders

    US Hepatology Partner

    EU Hepatology Partner

    Global Hepatology Partner

    An Introduction to Liver Disorders

    Hepatology covers hepatitis, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD), cirrhosis and rarer conditions such as autoimmune and cholestatic liver diseases. Despite numerous advances, liver-related mortality has remained stable for over 30 years. The World Health Organization has set targets for hepatitis C elimination by 2030. Immunotherapy and combination therapies have greatly increased the efficacy of the treatment of hepatocellular carcinoma (HCC). However, as a result of the increasing prevalence of obesity, NAFLD is reaching epidemic proportions and poses a major challenge to global public health. There is an urgent need for long-term management strategies and pharmacological interventions for NAFLD.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Liver Disorders Content

    Liver Disorders, Rare Autoimmune Diseases
    Watch Time: 34 mins
    touchEXPERT OPINIONS
    Primary biliary cholangitis: Appraising the changing therapeutic landscape
    CE/CME ACCREDITED Dr Mitchell L Shiffman Translations available:

    Dr Mitchell L Shiffman explores the current and future management of primary biliary cholangitis

    Learning objectives
    Learning Objectives
    • Describe the objectives of PBC treatment in the first line and how patients are risk stratified
    • Discuss treatment sequencing approaches to optimize outcomes in patients with PBC
    • Recall the latest data for new and emerging treatments for PBC
    Liver Disorders, Rare Autoimmune Diseases
    Watch Time: 38 mins
    touchMDT
    Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
    CE/CME ACCREDITED Prof. Gideon Hirschfield, Prof. Sonja Ständer, Ms Michelle Clayton, Mrs Collette Thain MBE Translations available:

    A multidisciplinary team and a patient advocate discuss the management of cholestatic pruritus in primary biliary cholangitis (PBC).

    Learning objectives
    Learning Objectives
    • Describe the burden of cholestatic pruritus in patients with PBC and the lack of awareness of addressing symptom control
    • Assess and monitor symptoms of cholestatic pruritus, and use individualized treatment strategies to improve outcomes in affected patients
    • Apply a comprehensive approach to patient management, involving patient education and counselling
    Liver Disorders
    Breakthroughs in MASH: Highlights from EASL 2024

    The EASL 2024 meeting offered a great opportunity for hepatologists from around the world to discuss the latest data and tackle challenges in liver disease. Metabolic dysfunction-associated steatohepatitis (MASH) was a hot topic, with several exciting studies making waves. This article highlights some of the most interesting and promising research on MASH presented at the […]

    Liver Disorders, Rare Autoimmune Diseases
    Watch Time: 38 mins
    touchIN CONVERSATION
    Achieving best practice management of primary biliary cholangitis, now and in the future
    CE/CME ACCREDITED Dr Palak Trivedi, Prof. Gideon Hirschfield Translations available:

    Watch two specialists in autoimmune liver disease discuss best practice in the management of primary biliary cholangitis, including assessing emerging therapies and personalization of care.

    Learning objectives
    Learning Objectives
    • Describe the recommendations for diagnosis and management of patients with primary biliary cholangitis
    • Evaluate emerging treatment options for patients with primary biliary cholangitis
    • Review and implement individualized management for patients with primary biliary cholangitis
    Liver Disorders
    Developed by Touch
    Arjan Bredenoord, UEG Week 2022: Analysis of the LIBERTY-EoE-TREET study of dupilumab in eosinophilic esophagitis
    Watch Time: 4 mins

    LIBERTY-EoE-TREET (NCT03633617) was a phase 3, randomized, 3-part study investigating the efficacy and safety of dupilumab in eosinophilic esophagitis (EoE). It was a pleasure to talk with Prof. Arjan Bredenoord (Amsterdam UMC, Amsterdam, the Netherlands) around his analysis of the LIBERTY-EoE-TREET study, looking at the efficacy of dupilumab in patients with EoE with and without […]

    Liver Disorders
    Developed by Touch
    Maria Buti, EASL ILC 2022: Impact of bulevirtide on patient-reported outcomes
    Watch Time: 5 mins

    MYR301 (NCT03852719) is a phase 3 study evaluating the long-term efficacy and safety of bulevirtide in people living with chronic hepatitis delta infection (CHD). In this interview, Prof. Maria Buti (Vall d’Hebron University Hospital, Barcelona, Spain) discusses the results from the exploratory analysis of MYR301, investigating the health-related quality of life (HRQOL) benefits of treatment […]

    Liver Disorders
    Developed by Touch
    Thomas Berg, EASL: Unmet needs in diagnosis and treatment of hepatitis
    Watch Time: 3 mins

    touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D. Question: What are the unmet needs in diagnosis and treatment of hepatitis? (0:20) Disclosures: Dr Thomas Berg has received grant/research […]

    COVID-19, Liver Disorders
    Nancy Reau, DDW 2021: Hepatic Manifestations of COVID-19

    It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection. Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 May 2021 May 2021. Questions Could you give us a brief overview of the spectrum […]

    Rheumatoid Arthritis, Liver Disorders
    Peter C Taylor, ACR 2020 – HCQ in the prevention of NAFLD (Part 2)

    In Part 2 of our ACR Convergence Highlights coverage, Peter C Taylor (University of Oxford, Oxford, UK) discusses the results of an exploratory study into the association of Hydroxychloroquine (HCQ) use and the development of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with RA. The full abstract ‘Association of Hydroxychloroquine Use with Development of Non-Alcoholic […]

    In Partnership with...
    Useful Links:
    About us Society Partners Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchIMMUNOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup